Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2018

Pharma News, 2018

Body-clock study could pave way for new asthma treatment: UK expert
Body-clock study could pave way for new asthma treatment: UK expert
LONDON, Sept.
GSK says U.S. FDA wants more information on pulmonary drug
GSK says U.S. FDA wants more information on pulmonary drug
LONDON (Reuters) - GlaxoSmithKline said on Friday that U.
AstraZeneca’s first Breakthrough Therapy Designation for a respiratory medicine
AstraZeneca’s first Breakthrough Therapy Designation for a respiratory medicine
AstraZeneca and its partner Amgen Inc.
Chinese researchers identify potential new antibiotic
Chinese researchers identify potential new antibiotic
LONDON, Sept.
Perrigo's OTC Version of Diarrhea Drug Imodium Gets FDA Nod
Perrigo's OTC Version of Diarrhea Drug Imodium Gets FDA Nod
Perrigo Company plc PRGO announced that the FDA has approved store brand over-the-counter ("OTC") equivalent of Johnson & Johnson JNJ owned Imodium Multi-Symptom Relief tablet.
Vertex Completes Enrollment of Two Phase 3 Studies of VX-659 in Triple Combination with Tezacaftor and Ivacaftor for the Treatment of Cystic Fibrosis
Vertex Completes Enrollment of Two Phase 3 Studies of VX-659 in Triple Combination with Tezacaftor and Ivacaftor for the Treatment of Cystic Fibrosis
BOSTON, MA, USA I September 06, 2018 I Vertex Pharmaceuticals Incorporated (Nasdaq.
ITF Pharma Announces FDA Approval Of TIGLUTIK™ (Riluzole) Oral Suspension For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)
ITF Pharma Announces FDA Approval Of TIGLUTIK™ (Riluzole) Oral Suspension For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)
BERWYN, PA, USA I September 6, 2018 I ITF Pharma, a U.
BTG buys Irish med device group Novate
BTG buys Irish med device group Novate
Specialist healthcare group BTG has snapped up med tech group Novate Medical in a deal potentially worth $150 million.
Gilead, Galapagos’ filgotinib succeeds in PhII ankylosing spondylitis trial
Gilead, Galapagos’ filgotinib succeeds in PhII ankylosing spondylitis trial
A mid-stage trial assessing Gilead and Galapagos’ JAK 1 inhibitor filgotinib in ankylosing spondylitis has hit its targets.
GlaxoSmithKline to cut 650 US jobs, reinvest in R & D
GlaxoSmithKline to cut 650 US jobs, reinvest in R & D
RALEIGH, N.
Walking 20 minutes a day cuts women's heart failure risk by 25%, first ever study on the topic reveals
Walking 20 minutes a day cuts women's heart failure risk by 25%, first ever study on the topic reveals
Walking more - not faster - can significantly lower the risk of heart failure in older women, according to the first ever study on the subject.
Novartis unloads U.S. assets at loss to bargain-hunting Aurobindo
Novartis unloads U.S. assets at loss to bargain-hunting Aurobindo
ZURICH/BENGALURU (Reuters) - New Novartis Chief Executive Vas Narasimhan has further reshaped the Swiss drugmaker, announcing on Thursday he is selling U.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand